Wednesday, July 8, 2026

biotech · Advanced Solid Tumor · Solid Tumor, Adult · IMMX

Immix Biopharma

Immix Biopharma clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Los Angeles, USA HQ
2012 Founded
39 Employees
Public company Type
IMMX · NYSE Ticker
Company details
Status
Public
HQ
Los Angeles, USA
Founded
2012
Employees
39
Programs
3
Drugs
2
Patents
2
Intelligence · Clinical Programs

Immix Biopharma projects

3 ClinicalTrials.gov programs sponsored by Immix Biopharma.

Immix Biopharma has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. IMX-110 combined with Tislelizumab

    Immix Biopharma

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial
  2. Imx-110

    Immix Biopharma

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial
  3. NXC-201 CAR-T

    Immix Biopharma

    Light Chain (AL) Amyloidosis

    phase 2 mab active

    1 trial

Frequently asked questions

How many clinical projects does Immix Biopharma have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.